Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)
Study Details
Study Description
Brief Summary
The trial is designed to evaluate prevalence of fragility fracture, their impact on quality of life of SLE patients and disease or treatment variables such as steroids dosage or use of specific drugs like hydroxychloroquine, DMARDs or belimumab. Patients will perform DXA evaluation, blood tests and PROs questionnaires. Moreover, the investigators want to correlate those variables to bone turnover markers and bone metabolism modulators. A secondary aim is also to assess the fracture risk of those patients as described by FRAX and DEFRA tools.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Prevalence of osteoporosis [1 visit - 1 hour]
percentage of patient with osteoporosis defined by WHO definition with T score
- Prevalence of fragility fractures [1 visit 1 hour]
percentage of patients with fragility fractures
- EQ5D [1 visit - 1 hour]
scores at questionnaire on quality of life EQ5D = EuroQol 5 dimension 5 L; (min 1-1-1-1-1, max 5-5-5-5-5 higher score worse + EQ VAS min 0, max 100 higher score better quality of life)
- FACIT-F [1 visit - 1 hour]
scores in fatigue as for questionnaire FACIT-F (Functional Assessment of Chronic Illness Therapy - Fatigue; min 0 - max 52, higher score less fatigue)
- SF-36 v2 [1 visit - 1 hour]
scores on quality of life with SF36 v2 (Short Form 36 version 2 Health Survey; min 0 - max 100, higher score better health)
- HADS [1 visit - 1 hour]
scores on mood disorder scale HADS (Health Anxiety and Depression Scale; min 0 - Max 42, higher score worse anxiety)
- MMAS-8 [1 visit - 1 hour]
scores on therapy adherence (Morinsky Medication Adherence Score; min 0 - max 8, higher score better adherence)
- PGA [1 visit - 1 hour]
Patient global assessment ( VAS scale 0-10) higher score worse health
- influence of SLE medication - glucocorticoid [1 visit - 1 hour]
The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in cumulative corticosteroid dose (mg)
- influence of SLE medication - hydroxychloroquine [1 visit - 1 hour]
The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage of hydroxychloroquine users.
- influence of SLE medication - immunosuppressant [1 visit - 1 hour]
The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage percentage of immunosuppressant users
- influence of SLE medication - biologics [1 visit - 1 hour]
The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage of percentage of biologics ( e.g. belimumab) users.
Secondary Outcome Measures
- Descriptive statistics of study population - 1 [1 visit - 1 hour]
The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to clinical variables - SLE disease duration
- Descriptive statistics of study population - 2 [1 visit - 1 hour]
The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to clinical variables - SDI ( SLICC Damage index - from 0, higher score higher disease damage accrual)
- Descriptive statistics of study population - 3 [1 visit - 1 hour]
The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to demographic variable - Age ( years)
- Descriptive statistics of study population - 4 [1 visit - 1 hour]
The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to demographic variable - gender ( % females)
- serum bone biomarkers - BAP [1 visit - 1 hour]
bone alkaline phosphatase (BAP) (ug/L) level in study population and difference by fracture status
- serum bone biomarkers - P1NP [1 visit - 1 hour]
N-terminal propeptide of type I procollagen - P1NP (ng/ml) level in study population and difference by fracture status
- serum bone biomarkers - CTX [1 visit - 1 hour]
C-terminal telopeptide of type I collagen (CTX) (ng/ml), level in study population and difference by fracture status
- serum bone biomarkers - PTH [1 visit - 1 hour]
parathormone (PTH) pg/ml level in study population and difference by fracture status
- serum bone biomarkers - vitamin D(OH) [1 visit - 1 hour]
25OH vitamin D (ng/ml), level in study population and difference by fracture status
- serum bone biomarkers - Sclerostin [1 visit - 1 hour]
sclerostin (pmol/L) level in study population and difference by fracture status
- serum bone biomarkers - Dkk1 [1 visit - 1 hour]
Dkk1 (pmol/L) level in study population and difference by fracture status
- serum bone biomarkers - RANKL [1 visit - 1 hour]
RANKL (pg/ml) level in study population and difference by fracture status
- serum bone biomarkers - OPG [1 visit - 1 hour]
OPG (pg/ml level) in study population and difference by fracture status
- Fracture risk calculation by FRAX tool [1 visit - 1 hour]
FRAX fracture risk assessment ( % risk major fracture in 10 yrs)
- Fracture risk calculation by DEFRA tool [1 visit - 1 hour]
DEFRA fracture risk assessment ( % risk major fracture in 10 yrs)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
SLE fulfilling 2019 ACR/EULAR or 2012 SLICC criteria
-
willing to perform DXA/ x-Ray investigation (common clinical practice)
-
willing to donate blood sample
-
willing to complete questionnaires
-
the patients should be in a stable disease activity.
Exclusion Criteria:
-
Uncontrolled endocrinological disease.
-
metabolic bone disease other than osteoporosis ( e.g. Paget disease).
-
celiac disease, inflammatory bowel disease or pancreatic exocrine deficiency resulting in malabsorption
-
patients lacking medication history information (SLE and bone related medications).
-
Have any other clinically significant abnormal laboratory value in the opinion of the investigator
-
Have any intercurrent significant medical illness that the investigator considers would make the candidate unsuitable for the study.
-
The patients shouldn't be enrolled during a moderate to severe flare of disease requiring an escalation of therapy ( especially glucocorticoid) - no new BILAG A or B in the last 3 months.
-
Pregnant patients or during the first year after child birth.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | AOUI Verona - UOC Reumatologia | Verona | Italy | 37134 |
Sponsors and Collaborators
- Azienda Ospedaliera Universitaria Integrata Verona
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3875CESC